Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service pacemaker, ICD & CRT implantation cases in Maryland: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (249 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 49 | 3,641 | 14% |
| 2020 | 48 | 3,121 | 15% |
| 2021 | 56 | 3,586 | 19% |
| 2022 | 50 | 3,226 | 22% |
| 2023 | 54 | 3,237 | 25% |
| 2024 | 50 | 3,355 | 28% |
| 2025 from claims | – | 3,052 2,794–3,239 | 29% |
| 2026 forecast | – | 3,144 2,767–3,613 | 29% |
| 2027 forecast | – | 3,184 2,724–3,776 | 29% |
| 2028 forecast | – | 3,226 2,693–3,927 | 30% |
| 2029 forecast | – | 3,267 2,670–4,071 | 31% |
| 2030 forecast | – | 3,309 2,652–4,211 | 31% |
Pacemaker, leadless, ICD, S-ICD, CRT, and generator replacements. Professional codes (what the surgeon bills): CPT 33206, 33207, 33208, 33274, 33249, 33270, 33262, 33263, 33264; the hospital bills MS-DRG 242, 243, 244, 226, 227, 275, 276, 277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 41% of the cases CMS names in Maryland; 29 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 38% inpatient hospital, 61% hospital outpatient, 1% surgery center.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Surgery center |
|---|---|---|---|
| 2026 · ~3,100 | ~1,200 | ~1,900 | ~23 |
| 2027 · ~3,200 | ~1,200 | ~1,900 | ~25 |
| 2028 · ~3,200 | ~1,300 | ~1,900 | ~27 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 60% (61% in 2025).
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 252 | 13,502−2.8%/yr | −2.8%/yr | 6.3 | 8% | 13,600 in 2030+0.2%/yr |
| Texas | 220 | 11,904−3.2%/yr | −3.2%/yr | 5.8 | 7% | 12,400 in 2030+0.7%/yr |
| Virginia | 89 | 5,164−2.2%/yr | −2.2%/yr | 5.1 | 6% | 5,360 in 2030+0.6%/yr |
| North Carolina | 100 | 4,900−3.4%/yr | −3.4%/yr | 5.1 | 0% | 5,080 in 2030+0.6%/yr |
| Tennessee | 79 | 4,568−3.7%/yr | −3.7%/yr | 6.8 | 1% | 4,440 in 2030−0.5%/yr |
| Georgia | 88 | 4,562−3.7%/yr | −3.7%/yr | 5.5 | 0% | 5,000 in 2030+1.5%/yr |
| South Carolina | 68 | 3,816−0.8%/yr | −0.8%/yr | 5.8 | 1% | 4,480 in 2030+2.7%/yr |
| Arkansas | 40 | 2,424−5.8%/yr | −5.8%/yr | 6.6 | 0% | 2,150 in 2030−1.9%/yr |
| Alabama | 51 | 2,357−6.8%/yr | −6.8%/yr | 5.6 | 0% | 2,180 in 2030−1.3%/yr |
| Oklahoma | 41 | 2,337−5.8%/yr | −5.8%/yr | 5.0 | 3% | 2,280 in 2030−0.4%/yr |
| Louisiana | 38 | 2,134−6.6%/yr | −6.6%/yr | 5.5 | 9% | 1,970 in 2030−1.3%/yr |
| Kentucky | 43 | 2,123−7.2%/yr | −7.2%/yr | 4.8 | 0% | 1,980 in 2030−1.2%/yr |
| Mississippi | 27 | 1,614−8.6%/yr | −8.6%/yr | 4.4 | 6% | 1,490 in 2030−1.3%/yr |
| West Virginia | 18 | 1,107−1.5%/yr | −1.5%/yr | 5.5 | 0% | 1,020 in 2030−1.4%/yr |
| Delaware | 13 | 723−4.3%/yr | −4.3%/yr | 4.3 | 0% | 790 in 2030+1.4%/yr |
| District of Columbia | 10 | 494−2.1%/yr | −2.1%/yr | 8.1 | 0% | 510 in 2030+0.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| EP ablation | 43 | 2,149+8.3%/yr | +8.3%/yr | 2.20.6× | 0% | 3,540 in 2030+8.7%/yr |
| LAA occlusion & loop recorders | 56 | 1,714+8.2%/yr | +8.2%/yr | 1.80.5× | 35% | 3,130 in 2030+11%/yr |
Pacemaker, ICD & CRT implantation in every state, and its device makers · Every procedure market in Maryland · Every state · Compare with Florida
Boston Scientific leads with 55% of company spending on these surgeons in 2025, +28 pts on 2024.
In 2025, 8 companies reported engagement with Maryland’s surgeons worth $254K in consulting, speaking, meals and travel tied to these products, about $5,075 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 334 clearances and approvals in the category, 3 recalled product lines (2 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.